Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 17 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 17 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History